
    
      A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the
      effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on
      cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate
      Alzheimer's disease. (REFLECT-1)
    
  